Elena Herrera

Dr. Elena Herrera-Carrillo is a biochemist by training and Group Leader at the Institute of Parasitology and Biomedicine “López-Neyra” (IPBLN-CSIC) in Granada, Spain. Prior to joining IPBLN-CSIC, she spent 14 years at Amsterdam UMC in the Netherlands, where she led a research group in gene therapy and served as an Associate Professor. In 2025, she relocated her laboratory to Spain, where she continues to advance her research with a primary focus on HIV cure strategies.

With almost 20 years of experience in HIV research, Dr. Herrera-Carrillo has extensive expertise in molecular virology and gene delivery technologies. Throughout her career, she has developed innovative antiviral and gene therapy approaches based on RNA interference (RNAi), peptide-based virus entry inhibitors, and CRISPR-Cas genome editing technologies. Her work has employed a range of delivery platforms, including lentiviral vectors (LV), adeno-associated viral vectors (AAV), and lipid nanoparticles (LNPs), with a particular emphasis on targeted delivery strategies. Her research aims to translate fundamental discoveries into novel therapeutic approaches for HIV and other infectious diseases, advancing the development of durable treatments and curative interventions.